Quality of life (QoL) improvements in 1,464 patients (pts) with metastatic breast cancer (MBC) receiving capecitabine (X) in Brazil: Updated results from a large pt cohort, including analysis as a function of pts’ ECOG PS

8599 Background: The oral fluoropyrimidine capecitabineis highly active and well tolerated as single-agent therapy and extends survival when added to docetaxelin pretreated MBC. QoL data would en...